Developing precision antibiotics against multidrug-resistant bacteria
Drug-resistant bacterial infections narrow treatment options and increase the risk of severe illness and death. They can prolong hospital stays and increase the need for intensive care, while the antibiotic development pipeline offers few new medicines.
DimiCare Biotech is developing precision antibiotics for multidrug-resistant infections. Its lead programme targets Staphylococcus aureus, with treatments designed to spare beneficial microbes and limit the emergence of resistance.
What stands out about DimiCare Biotech
Established in vitro and in vivo proofs of concept for its antimicrobial programme during development beginning in 2023.
Won the i-Lab 2025 innovation competition for its precision-antibiotic development project.
Spun out of Université Côte d’Azur, Inserm and CNRS to develop precision treatments for resistant infections.
Secured LabEx/IdEx funding for its founding project through Université Côte d’Azur’s Young Entrepreneur Program, financing an initial engineer position.
Founded by scientists including Laurent Boyer, an Inserm research director specialising in microbiology and immunology.
Joined the Provence-Côte d’Azur Business Incubator in 2026 to support development of its antimicrobial company.
Won the Pépite France award in November 2025 for its antimicrobial venture.
Co-founder Laurent Boyer studied at Harvard Medical School from 2006 to 2009.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.